Prolonged Hypercoagulability Following Major Liver Resection for Malignancy

Launched by WESTERN UNIVERSITY, CANADA · Nov 22, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well a special blood test called thromboelastography (TEG) can identify blood clotting risks after major liver surgery for cancer. The researchers want to find out if giving patients a longer course of medication to prevent blood clots, known as thromboprophylaxis, can help reduce complications after surgery. Typically, patients receive this medication for 30 days, but some studies suggest that the risk of blood clots can last up to 3 months. In this trial, half of the participants will receive the medication for 90 days, while the other half will stick to the standard 30 days.

To be eligible for this study, participants need to be adults over 18 years old who are having major liver surgery for cancer and need to take medication to prevent blood clots afterward. Participants should be comfortable giving themselves daily injections or have someone help them. Throughout the study, participants will have their blood tested and will be monitored for any blood clotting complications as well as their overall health for up to three years after surgery. This trial is not yet recruiting, but it aims to provide valuable information on improving care for patients undergoing liver surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged 18 years or older at the time of enrollment.
• • 2. Requiring major liver resection (\>2 liver sections) for any oncologic indication.
• • 3. Requiring postoperative thromboprophylaxis will be included.
• • 4. Willing and able to perform subcutaneous injections according to the study protocol, or receive injections form a caregiver delegated by the participant.
• Exclusion Criteria:
• • 1. Anyone below 18 years of age.
• • 2. Patients on current anticoagulant and/or antiplatelet therapy
• • 3. Patients with a history of thrombotic events
• • 4. Patients with a coagulation disorder.
• • 5. Patients with recognized thrombophilia.
• • 6. Patients who cannot understand/speak or read in English.